I was told after Sinovac 3rd Dose you still have to take a 4th dose of Pfizer or Moderna otherwise you are not considered vaxxed. Therefore, I asked the nurse why and she told me MOH researched that Sinovac is not strong enough and 4th Dose of Pfizer or Moderna is needed.
Is this a circus?? Anyone can help to confirm this?
After 3 doses of Sinovac, who came out with this conclusion that 4th Dose must be other brands in order to be considered vaxxed? Is it because MOH needs to clear stocks??
Even SINOVAC themselves hv not had studies on 4th shots. But confirm 3rd shot, in other countries considered as boosters but in sinkieland considered as completing Primary VAX.
Results hv shown its as good as those MRNA out there.
It's all driven politically, not scientifically.
Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave
2022-03-23
A study of University of Hong Kong revealed that three shots of CoronaVac offered appromixtely 98% protection against death or severe illness in those over 60 years old, underscoring the importance of boosters for those who have received that Covid-19 shot.
Specifically, after the three-dose booster vaccination for people over 60 years old, the effective rate of SINOVAC vaccine against severe illness is 97.9%, and the effective rate of BioNTech vaccine was 98.0%. The effective rates in preventing death of SINOVAC and BioNTech were 98.3% and 98.1% respectively.
The study also showed that for people over 60 years old, in the case of completing two doses of vaccine, the effective rates of SINOVAC and BioNTech in preventing severe illness were 72.2% and 89.6%, respectively; the effective rates in preventing death were 77.4% and 92.3%, respectively. Real-world studies have confirmed the effectiveness of China's inactivated vaccine, and its safety advantages cannot be ignored. It can avoid relatively serious adverse reactions such as a large number of fever, myocarditis, and acute allergic reactions caused by the large-scale use of mRNA vaccines.
The findings, which analyzed patients hospitalized during HK continuing Omicron wave, have implications for Covid strategies in China. Chinese Official data showed that, the vaccine coverage of people who had received at least two shots was 88%, and that 659 million people had received a booster shot. However, according to offical present, there is still room for further improvement in the vaccination rate of the elderly in some areas, as about half of the elderly age of 80 and above haven’t been vaccinated at all.
In October 2021, the World Health Organization recommended a third dose of CoronaVac to people aged 60 who had received the SINOVAC shot.
This study support three doses of CoronaVac can benefit over two in preventing severe illness or death in people over the age of 60.
http://www.sinovac.com/news/shownews.php?id=1426&lang=en
https://www.wsj.com/articles/hong-k...11647952641?reflink=desktopwebshare_permalink
March 23, 2022
阅读简体中文版閱讀繁體中文版
Two doses of China’s Sinovac vaccine offered older people only a moderately high level of protection against severe disease and death from Covid-19, but a third dose significantly bolstered their defenses, according to a
new study by scientists in Hong Kong.
The study, based on patients infected during the current devastating
Omicron wave in Hong Kong, serves as a cautionary note for mainland China, where Sinovac is a pillar of the country’s vaccination program. Many older people there have yet to receive booster shots.
For people 60 and older, two Sinovac doses were 72 percent effective against severe or fatal Covid-19 and 77 percent effective against Covid-related death, the study found. Those levels of protection were lower than those provided by two Pfizer-BioNTech doses. The same study found they were 90 percent effective against severe or fatal Covid and 92 percent effective against death among Hong Kong residents of the same age group.
A Sinovac booster shot helped considerably, proving to be 98 percent effective against severe or fatal Covid among people at least 60 years old, the study found.
Yanzhong Huang, a global health expert at the Council on Foreign Relations, said that the results highlighted the urgency for mainland China to accelerate its lagging booster campaign. “There’s a lot of work for the government to do to make sure this segment of the population receives the booster shots,” he said.
The study’s authors, who are scientists at the University of Hong Kong, noted that the city’s booster program began just recently, making it difficult to determine how long protection from a third dose would last.
Because people with underlying health conditions in Hong Kong were more likely to resist getting vaccinated, they said, it was also possible that those who chose to be vaccinated or boosted were healthier in the first place, inflating estimates of how protective the vaccines initially were.
Sinovac, a private Chinese company that makes the vaccine, is one of two manufacturers of Covid shots available in China. Vaccines using mRNA technology, like those made by Pfizer-BioNTech and Moderna, are not available there.
The new study highlights the potential consequences for China, which has relied heavily on Sinovac and is battling its biggest Covid outbreak in two years. More than 87 percent of China’s population has been vaccinated. But just over half of people 80 and older have had two shots, and less than 20 percent of people in that age group have received a booster, Zeng Yixin, a vice minister of the National Health Commission, said recently.
Editors’ Picks
You Want Your Child Vaccinated, but Your Ex Says No
Gazing at the ‘Black Sun’: The Transfixing Beauty of Starling Murmurations
How Film Forum Became the Best Little Movie House in New York
The new study from Hong Kong received funding from the Chinese Center for Disease Control and Prevention as part of what one of the study’s co-authors described this week as an effort to understand the comparative effectiveness of vaccines. It was posted online as a preprint, but has not yet been vetted by peer scientists for publication in a scientific journal.
Updated
April 4, 2022, 3:23 p.m. ET1 hour ago
1 hour ago
Sinovac’s vaccine performed similarly to Pfizer’s among younger people, even without a booster dose, the study found. In people younger than 60, two Sinovac doses were roughly 92 percent effective against severe or fatal Covid, whereas two Pfizer doses were about 95 percent effective.
Coronavirus Vaccine Tracker
A look at all the vaccines that have reached trials in humans.
Neither vaccine provided very much protection against mild or moderate Covid, though Pfizer’s offered more than Sinovac’s and a booster dose considerably lifted levels of protection. During the latest wave, people in Hong Kong have largely been infected by the subvariant of
Omicron known as BA.2. Like other versions of Omicron, BA.2 has infected many vaccinated people.
The Hong Kong wave is killing people at a rate exceeding that of almost any country since the coronavirus emerged — a result, in large part, of low vaccination rates among older residents. Almost 90 percent of people who died during the latest wave were not fully immunized, suggesting that getting shots to the most vulnerable is more important than the particular brand of vaccine.
Like Hong Kong, mainland China had largely succeeded in tamping down transmission of the virus before Omicron, leaving its population with very little immunity from previous infections.
Beyond China, Sinovac vaccines have also been critical in protecting people against severe Covid, especially in poorer countries. The vaccine is being used in 49 countries, including in South America and Africa.
But concerns about the protection it offered had already prompted the World Health Organization to
recommend in October that recipients 60 and older get a third dose.
Dr. Andrew Morris, an infectious disease specialist at Sinai Health and University Health Network in Toronto, who was not involved with the Hong Kong study, said that the results fit with
lab studies suggesting that Sinovac generated lower levels of neutralizing antibodies than mRNA vaccines, like Pfizer’s.
“I think what we’ll see is in countries that have relied heavily on Sinovac, if they don’t have boosting — especially with an mRNA booster, or even with Sinovac — they’re probably going to struggle with high rates of infection with this latest BA.2 wave,” he said.
Dr. Morris said that the results in Hong Kong, like those from other vaccine studies, were also highly dependent on how long it had been since people were administered the shots. Protection tends to weaken over time.
The results from the latest study about the effectiveness of third Sinovac doses might be taken as an encouraging sign by Chinese leaders that Chinese-made vaccines could remain the focus of their immunization campaign, said Dr. Huang, of the Council on Foreign Relations.
“Now, for the Chinese leaders, they don’t need to face a strong pressure to approve BioNTech’s vaccine,” he said.
https://www.nytimes.com/2022/03/23/health/sinovac-coronavirus-booster-hong-kong.html
